Ontario Teachers Pension Plan Board Trims Stake in Edwards Lifesciences Co. (NYSE:EW)

Ontario Teachers Pension Plan Board lessened its holdings in Edwards Lifesciences Co. (NYSE:EWFree Report) by 18.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,470 shares of the medical research company’s stock after selling 797 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Edwards Lifesciences were worth $265,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its position in shares of Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after buying an additional 1,488,791 shares in the last quarter. Telos Capital Management Inc. raised its position in Edwards Lifesciences by 158.2% during the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after purchasing an additional 56,000 shares in the last quarter. Arlington Trust Co LLC lifted its stake in Edwards Lifesciences by 5,092.4% during the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after purchasing an additional 12,069 shares during the last quarter. Versor Investments LP boosted its holdings in shares of Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after purchasing an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $1,587,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction on Monday, May 6th. The shares were acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Insiders sold a total of 180,707 shares of company stock worth $16,034,814 in the last three months. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Up 0.6 %

NYSE EW opened at $87.98 on Monday. The firm has a market capitalization of $53.02 billion, a PE ratio of 37.92, a P/E/G ratio of 3.22 and a beta of 1.10. The stock’s 50 day moving average is $89.68 and its 200 day moving average is $81.74. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Research analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EW. Stifel Nicolaus upped their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Friday, April 26th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Evercore ISI reduced their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. Finally, Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $94.31.

View Our Latest Stock Analysis on EW

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Recommended Stories

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.